CD28 and neoplasm: Notably, a clinical investigation by Ramos  et al. (20) demonstrated that CAR3 T cells against CD19 (CD28 and 41-BB) exhibited stronger anti-tumor activity than CAR2 T cells (CD28 only), with mild CRS, in 16 patients with relapsed/refractory non-Hodgkin lymphoma.